Payment overview · 2025
General Payments
$521.75
25 reported records · 11 companies
Healthcare provider profile · identity verified
Thomas James Schreiber, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DUBUQUE, IA · NPI 1659325694
Verified facts
What the public records show
CMS Open Payments records show Thomas James Schreiber, M.D. received $521.75 in general payments during 2025 across 25 reported records.
PFIZER INC. accounted for 35.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $183.96 | 35.3% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $81.31 | 15.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.86 | 8.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.36 | 8.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.96 | 6.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.81 | 6.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.35 | 4.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.13 | 4.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.46 | 3.9% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $17.91 | 3.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.64 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $521.75 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $183.96 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $58.97 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.75 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.86 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.36 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.36 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.96 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.56 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.56 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.81 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.81 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
125 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 529 | 130 |
| Omeprazole | Omeprazole | 463 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 417 | 64 |
| Furosemide | Furosemide | 384 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 318 | 75 |
| Losartan Potassium | Losartan Potassium | 291 | 69 |
| Potassium Chloride | Potassium Chloride | 286 | 59 |
| Lisinopril | Lisinopril | 266 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 262 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 251 | 66 |
| Gabapentin | Gabapentin | 222 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 196 | 45 |
| Trazodone Hcl | Trazodone Hcl | 178 | 33 |
| Simvastatin | Simvastatin | 168 | 43 |
| Allopurinol | Allopurinol | 147 | 30 |
| Donepezil Hcl | Donepezil Hcl | 144 | 25 |
| Prednisone | Prednisone | 144 | 51 |
| Warfarin Sodium | Warfarin Sodium | 142 | 25 |
| Spironolactone | Spironolactone | 127 | 31 |
| Eliquis | Apixaban | 125 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 27 |
| Sertraline Hcl | Sertraline Hcl | 113 | 20 |
| Glimepiride | Glimepiride | 110 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 19 |
| Metformin Hcl | Metformin Hcl | 104 | 28 |
| Carvedilol | Carvedilol | 103 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 101 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 26 |
| Jardiance | Empagliflozin | 99 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | suppressed |
| Alprazolam | Alprazolam | 96 | 20 |
| Atenolol | Atenolol | 93 | 21 |
| Montelukast Sodium | Montelukast Sodium | 92 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 85 | 14 |
| Mirtazapine | Mirtazapine | 81 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 25 |
| Famotidine | Famotidine | 69 | 18 |
| Januvia | Sitagliptin Phosphate | 68 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 13 |
| Sucralfate | Sucralfate | 66 | 13 |
| Celecoxib | Celecoxib | 65 | 15 |
| Xarelto | Rivaroxaban | 63 | 11 |
| Cephalexin | Cephalexin | 58 | 39 |
| Meloxicam | Meloxicam | 57 | 13 |
| Irbesartan | Irbesartan | 55 | 11 |
| Myrbetriq | Mirabegron | 55 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 55 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 42 |
| Ezetimibe | Ezetimibe | 52 | 11 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Bupropion Xl | Bupropion Hcl | 51 | 16 |
| Amoxicillin | Amoxicillin | 50 | 28 |
| Nystatin | Nystatin | 46 | 14 |
| Metformin Hcl Er | Metformin Hcl | 45 | 11 |
| Glipizide Er | Glipizide | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Azithromycin | Azithromycin | 36 | 32 |
| Finasteride | Finasteride | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 14 |
| Rasagiline Mesylate | Rasagiline Mesylate | 32 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 27 |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Baclofen | Baclofen | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 27 |
| Lorazepam | Lorazepam | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 18 |
| Pregabalin | Pregabalin | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Clonazepam | Clonazepam | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $521.75 · 25 records | PFIZER INC. | AREXVY, Cologuard Collection Kit, EOHILIA, Heplisav-B, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error